CRUKD/24/002 A CRUK Phase II open label trial in participants with metastatic pancreatic adenocarcinoma (PDAC) of ginisortamab (UCB6114), a first in class anti-gremlin1 mAb, given iv with 1st line SOC nab-paclitaxel & gemcitabine or in combination with MEK inhibitor maintenance therapy

An abstract will be uploaded at a later point

University of Glasgow

Complete our application form to express your interest and we'll guide you through the process.

Start Year 2023

End Year 2027

Grantees 1